Cough Syrups Global Market Report 2025

The cough syrups market size has grown strongly in recent years. It will grow from $6.36 billion in 2024 to $6.8 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth during the historic period can be attributed to the rising incidence of respiratory infections, increased awareness of self-medication, expansion of over-the-counter (OTC) availability, escalating pollution levels, and a growing geriatric population.

The cough syrups market size is expected to see strong growth in the next few years. It will grow to $8.75 billion in 2029 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to the rising demand for natural and herbal formulations, increasing preference for sugar-free and alcohol-free variants, expansion of online retail channels, growing disposable incomes in emerging economies, and advancements in drug formulation technologies. Key trends during the forecast period include the integration of artificial intelligence in product development, creation of personalized cough syrups, innovation in eco-friendly packaging solutions, progress in digital health monitoring tools, and development of pediatric-friendly formulations.

The rising prevalence of respiratory disorders is expected to drive the growth of the cough syrups market moving forward. Respiratory disorders are medical conditions that affect the lungs and other parts of the respiratory system, disrupting normal breathing. This increase is attributed to greater exposure to pollutants, allergens, and infections, which has led to higher demand for fast, accessible, and effective symptom relief treatments. Cough syrups assist in managing respiratory symptoms, soothing the airway, and improving breathing by addressing cough, throat irritation, and mucus congestion. For example, in February 2025, MedRxiv, a U.S.-based open-access online archive and distribution server, reported that hospitalizations related to respiratory viruses rose from 9.3% in late December 2024 to 9.6% in late January 2025, marking a 3.1% increase within one month. Thus, the growing prevalence of respiratory disorders is fueling the expansion of the cough syrups market.

Leading companies in the cough syrups market are focusing on creating innovative formulations, such as herbal cough syrups, to cater to the increasing consumer preference for natural and side-effect-free treatments. Herbal cough syrups are plant-based liquid remedies that utilize natural ingredients like tulsi, ginger, and licorice to soothe the throat and relieve cough without synthetic chemicals. For example, in August 2024, Avalon Pharma, a pharmaceutical company based in Saudi Arabia, launched Co-pan, an innovative herbal cough syrup that is the first and only SFDA-approved product of its kind suitable for both adults and children aged two years and above. This sugar-free and alcohol-free syrup offers proven effectiveness and high tolerability, particularly for pediatric patients, and includes a child-friendly dosing syringe. The launch of Co-pan underscores Avalon Pharma’s dedication to expanding its diverse product portfolio and reinforcing its leadership in the respiratory and herbal medicine sectors, aligning with its ongoing growth and innovation strategy within the Kingdom’s healthcare industry.

In November 2022, PAI Pharma, a U.S.-based pharmaceutical company, acquired VistaPharma for an undisclosed sum. Through this acquisition, PAI Pharma aims to strengthen its leadership in unit-dose and liquid medicines by expanding its product portfolio and improving its capacity to consistently supply a broad range of pharmaceuticals, especially for hospitals, retail pharmacies, and addiction treatment centers. VistaPharma is an India-based pharmaceutical firm that produces and distributes liquid medications, including cough syrups.

Major players in the cough syrups market are Pfizer Inc., Johnson & Johnson Services Inc., The Procter & Gamble Company, Roche Holding AG, Merck & Co. Inc., Bayer Aktiengesellschaft, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc, Teva Pharmaceutical Industries Limited, Boehringer Ingelheim GmbH, Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Cipla Limited, Glenmark Pharmaceuticals Ltd., Dabur India Limited, Alkem Laboratories Ltd., Prestige Consumer Healthcare Inc., Mankind Pharma Limited, The Himalaya Drug Company, Acella Pharmaceuticals LLC.

North America was the largest region in the cough syrup market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cough syrups report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cough syrups market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Cough syrups are liquid medicines used to alleviate coughing and related symptoms caused by colds, allergies, or respiratory infections. They contain active ingredients that either suppress the cough reflex (antitussives), assist in clearing mucus from the airways (expectorants), or reduce throat irritation and congestion.

The main types of cough syrups include expectorants, cough suppressants, antihistamines, and combination formulations. Expectorants are medications that help loosen and clear mucus from the lungs and airways, making it easier to cough up. These products are segmented by age group into pediatric and adult categories, with common ingredients including dextromethorphan, guaifenesin, codeine, and others. Major distribution channels comprise pharmacies, online retailers, supermarkets or hypermarkets, and additional outlets.

The cough syrups market research report is one of a series of new reports that provides cough syrups market statistics, including the cough syrups industry global market size, regional shares, competitors with the cough syrups market share, detailed cough syrups market segments, market trends, and opportunities, and any further data you may need to thrive in the cough syrups industry. This cough syrups market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cough syrups market consists of sales of decongestant syrups, antihistamine-based syrups, and mucolytic syrups. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.